Clinical Trials Directory

Trials / Available

AvailableNCT07000695

Managed Access Programs for TQJ230, Pelacarsen

Status
Available
Phase
Study type
Expanded Access
Enrollment
Sponsor
Novartis Pharmaceuticals · Industry
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

The purpose of this registration is to list Managed Access Programs (MAPs) related to TQJ230, pelacarsen

Detailed description

CTQJ230A12013M - Available - Managed Access Program (MAP) Cohort Treatment Plan (CTQJ230A12013M) to provide access to pelacarsen (TQJ230) for (Atherosclerotic Cardiovascular Disease, ASCVD)

Conditions

Interventions

TypeNameDescription
DRUGPelacarsenPatients receive Pelacarsen

Timeline

First posted
2025-06-03
Last updated
2025-06-03

Source: ClinicalTrials.gov record NCT07000695. Inclusion in this directory is not an endorsement.

Managed Access Programs for TQJ230, Pelacarsen (NCT07000695) · Clinical Trials Directory